Immunology & Rheumatology Clinical Trials

Statistical methods in immunology & rheumatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All immunology & rheumatology trials

727 results

• (DECIDE)Complete statistical analysis of the phase 3 DECIDE trial comparing BIIB019 (daclizumab high yield process) with interferon beta-1a in participants with relapsing-remitting multiple sclerosis, including trial design, registered endpoints, regression methods, efficacy…Phase 3Results postedn = 1,841NCT01064401
• 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 22NCT00117988
• 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00775268).Phase 1/2Results postedn = 31NCT00775268
• 1974Independent statistical analysis of Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 43NCT02777073
• 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis: Complete Statistical AnalysisIndependent statistical analysis of 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 405NCT01794741
• 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 72NCT04931667
• 3CIndependent statistical analysis of Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01120028).Phase 2/3Results postedn = 852NCT01120028
• 3MVIndependent statistical analysis of Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 341NCT00137631
• A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720: Complete Statistical AnalysisIndependent statistical analysis of A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 42NCT01578330
• A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica: Complete Statistical AnalysisIndependent statistical analysis of A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 16NCT01364389
• A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients: Complete Statistical AnalysisIndependent statistical analysis of A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 375NCT02589275
• A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 550NCT00682643
• A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 455NCT04230213
• A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 251NCT03809663
• A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN): Complete Statistical AnalysisIndependent statistical analysis of A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 134NCT00517530
• A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis: primary endpoint results, effect estimate with confidence…Phase 1Results postedn = 109NCT03210961
• A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).: Complete Statistical AnalysisIndependent statistical analysis of A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).: primary endpoint results, effect estimate…Phase 3Results postedn = 11NCT01734993
• A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 137NCT01610687
• A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP): Complete Statistical AnalysisIndependent statistical analysis of A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 9NCT02201290
• A Long-term Safety Study of QMF149 in Japanese Participants With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Long-term Safety Study of QMF149 in Japanese Participants With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 51NCT03100500
• A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle: Complete Statistical AnalysisIndependent statistical analysis of A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 101NCT01881113
• A Multicenter Prospective Randomized Control Study on Persona Total Knee System vs NexGen: Complete Statistical AnalysisIndependent statistical analysis of A Multicenter Prospective Randomized Control Study on Persona Total Knee System vs NexGen: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 332NCT03073941
• A Multicenter Study to Evaluate Functional Outcome After Knee Replacement: Complete Statistical AnalysisIndependent statistical analysis of A Multicenter Study to Evaluate Functional Outcome After Knee Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02494544).Phase NAResults postedn = 215NCT02494544
• A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors: Complete Statistical AnalysisIndependent statistical analysis of A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 47NCT02492100
• A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 239NCT02233803
• A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy: Complete Statistical AnalysisIndependent statistical analysis of A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 71NCT01705730
• A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 960NCT01309737
• A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1): Complete Statistical AnalysisIndependent statistical analysis of A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive…Phase 3Results postedn = 272NCT00604500
• A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use: Complete Statistical AnalysisIndependent statistical analysis of A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 90NCT01464346
• A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 295NCT01544348
• A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate…Phase 1Results postedn = 35NCT02961881
• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202): Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202): primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 60NCT02998476
• A Phase 2 Study For Patients With A Physician’s Diagnosis Of Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 386NCT00550446
• A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 26NCT01698801
• A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 1NCT02956122
• A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP): Complete Statistical AnalysisIndependent statistical analysis of A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 12NCT04669600
• A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 11NCT00590720
• A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 12NCT03759366
• A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 38NCT01377922
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial): primary endpoint results, effect…Phase 3Results postedn = 329NCT01100502
• A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic…Phase 3Results postedn = 1,101NCT01241591
• A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic…Phase 3Results postedn = 24NCT01433978
• A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy: primary endpoint…Phase 3Results postedn = 152NCT03930186
• A Phase I/II Trial of VR-CHOP in Lymphoma Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase I/II Trial of VR-CHOP in Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00634179).Phase 1/2Results postedn = 37NCT00634179
• A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 10NCT01563055
• A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma: primary…Phase 1/2Results postedn = 117NCT03677141
• A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 6NCT02042950
• A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 1NCT01378871
• A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 632NCT00316602
• A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 30NCT00858117

← All therapeutic areas